Inactive Instrument

ImmunoPrecise Antibodies Ltd. Toronto S.E.

IPA

CA45257F2008

ImmunoPrecise Antibodies Announces Departure of Stefan Lang, Chief Business Officer

May 09, 2022 at 08:03 am EDT

ImmunoPrecise Antibodies Ltd. announced the departure of Stefan Lang, Chief Business officer of IPA, effective immediately, and wishes him the best in his future endeavors.

Latest news about ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd. Announces an Expansion of Its LENSai Platform	Apr. 22	CI
ImmunoPrecise Antibodies And InterSystems Partner To Leverage AI In Life Sciences, Transforming Patient Care With Accelerated Discovery And Delivery Of Treatments	Apr. 12	CI
Transcript : ImmunoPrecise Antibodies Ltd., Q3 2024 Earnings Call, Mar 14, 2024	Mar. 14
ImmunoPrecise Antibodies Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	Mar. 14	CI
Certain Warrants of ImmunoPrecise Antibodies Ltd. are subject to a Lock-Up Agreement Ending on 6-MAR-2024.	Mar. 05	CI
Certain Stock Options of ImmunoPrecise Antibodies Ltd. are subject to a Lock-Up Agreement Ending on 6-MAR-2024.	Mar. 05	CI
Certain Common Shares of ImmunoPrecise Antibodies Ltd. are subject to a Lock-Up Agreement Ending on 6-MAR-2024.	Mar. 05	CI
ImmunoPrecise Antibodies Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023	Dec. 14	CI
Transcript : ImmunoPrecise Antibodies Ltd., Q2 2024 Earnings Call, Dec 14, 2023	Dec. 14
Top Premarket Gainers	Dec. 13	MT
Private Payrolls Increased Less Than Expected in November as US Equity Futures Rise Pre-Bell	Dec. 06	MT
Jobs Data in Focus as Exchange-Traded Funds, Equity Futures Lean Higher Pre-Bell Wednesday	Dec. 06	MT
Top Premarket Decliners	Dec. 06	MT
ImmunoPrecise Antibodies Plans Underwritten Offering of Common Stock; Shares Fall Pre-Bell	Dec. 06	MT
ImmunoPrecise Antibodies Ltd. Announces Board Changes	Nov. 27	CI
ImmunoPrecise Antibodies Develops the Lensai's Integrated Intelligence Platform Powered by Hyft Technology	23-10-20	CI
ImmunoPrecise Antibodies Names Kristin Taylor Interim Finance Chief	23-09-19	MT
ImmunoPrecise Antibodies Announces CFO Transition	23-09-19	CI
Transcript : ImmunoPrecise Antibodies Ltd., Q1 2024 Earnings Call, Sep 14, 2023	23-09-14
ImmunoPrecise Antibodies Ltd. Reports Earnings Results for the First Quarter Ended July 31, 2023	23-09-14	CI
ImmunoPrecise Antibodies Ltd. Announces Board Changes	23-09-06	CI
ImmunoPrecise Antibodies Ltd Issues a Response to Ingalls & Snyder LLC Filing	23-08-09	CI
Transcript : ImmunoPrecise Antibodies Ltd. - Special Call	23-07-19
ImmunoPrecise Antibodies Ltd. Reports Earnings Results for the Full Year Ended April 30, 2023	23-07-10	CI
ImmunoPrecise Antibodies Ltd. Auditor Raises 'Going Concern' Doubt	23-07-09	CI

Chart ImmunoPrecise Antibodies Ltd.

Duration

Period

More charts

ImmunoPrecise Antibodies Ltd. is a Canada-based biotherapeutic research and technology company. It leverages systems biology, multiomics modelling and artificial intelligence systems to support its technologies in bioplatform-based antibody discovery. Its services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners to discover and develop novel biologics. It utilizes custom antigen modeling, target analysis using Natural Language Processing and the HYFTTM analysis to lay the groundwork for the subsequent experimental phases. It offers services, such as immunogen design and manufacturing, B cell sorting incorporating its function-first B cell screening and sequencing, and the production and screening of custom, immune, and naive phage display libraries. It also operates LSA instrument platform, which is a provider of high-throughput large and small molecule screening and characterization solutions.

Sector

Pharmaceuticals

Calendar

2024-07-24 - Q4 2024 Earnings Release (Projected)

More about the company

Sector Biopharmaceuticals

	1st Jan change	Capi.
CSL LIMITED	-4.66%	87.53B
SAMSUNG BIOLOGICS CO.,LTD.	+2.63%	40.42B
BIOGEN INC.	-20.52%	29.48B
UCB	+57.79%	25.43B
INCYTE CORPORATION	-18.16%	11.49B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-44.02%	11.3B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-15.61%	11.1B
SWEDISH ORPHAN BIOVITRUM AB	+4.57%	8.75B
INNOVENT BIOLOGICS, INC.	-8.42%	7.99B

Biopharmaceuticals